Triple negative breast cancer: approved treatment options and their mechanisms of action.
Aditya MandapatiKiven Erique LukongPublished in: Journal of cancer research and clinical oncology (2022)
The recent approval and use of therapies such as Trodelvy, olaparib and Keytruda has its roots in the development of an understanding of signaling pathways that drive tumour growth. In the future, the emergence of novel drug delivery methods may help increase the efficiency of these therapies whiel also reducing adverse side effects.